MAP3K14 and myocardial infarction: A prespecified secondary analysis of the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) trial has demonstrated that Lp(a) held significant prognostic value for cardiovascular event risk (MACE: cardiac death, MI, stroke, coronary revascularization, or hospitalization for unstable angina) in patients with ASCVD only when hs‐CRP levels > 2 mg/L (HR: 1.13, 95% CI: 1.05–1.22, p = 0.002) [9].